2015
DOI: 10.1177/1071100715576370
|View full text |Cite
|
Sign up to set email alerts
|

Prospective Randomized Controlled Trial of Hindfoot and Ankle Fusions Treated With rhPDGF-BB in Combination With a β-TCP-Collagen Matrix

Abstract: Level I, prospective randomized study.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
46
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 53 publications
(46 citation statements)
references
References 20 publications
0
46
0
Order By: Relevance
“…From a clinical perspective, the FDA has approved the combination of PDGF-BB and β-tricalcium phosphate (TCP) for the treatment of periodontal defects (GEM21S®) [ 11 ]. Moreover, locally administered PDGF-BB and TCP (Augment®) have been investigated in acute wrist fractures [ 12 ] and proved to support hindfoot and ankle fusions [ 13 ]. Thus, supplementation of TCP with PDGF-BB is a favorable strategy in regenerative dentistry, orthopedics and traumatology.…”
Section: Introductionmentioning
confidence: 99%
“…From a clinical perspective, the FDA has approved the combination of PDGF-BB and β-tricalcium phosphate (TCP) for the treatment of periodontal defects (GEM21S®) [ 11 ]. Moreover, locally administered PDGF-BB and TCP (Augment®) have been investigated in acute wrist fractures [ 12 ] and proved to support hindfoot and ankle fusions [ 13 ]. Thus, supplementation of TCP with PDGF-BB is a favorable strategy in regenerative dentistry, orthopedics and traumatology.…”
Section: Introductionmentioning
confidence: 99%
“…Recent attempts to improve union rates have included the use of growth factors at the fusion site. In a randomized controlled trial, Daniels et al evaluated the efficacy and safety of recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) combined with an injectable, osteoconductive beta-tricalcium phosphate (b-TCP)-collagen matrix versus autograft (control) in ankle and hindfoot arthrodesis 39 . Complete fusion of all involved joints at 24 weeks was achieved in 84% of the patients treated with rhPDGF-BB and b-TCP-collagen matrix and in 65% of the patients treated with autograft (p < 0.001).…”
Section: Orthobiologics (Growth Factors)mentioning
confidence: 99%
“…This study also assessed clinical outcomes based on visual analog scale (VAS) score and lack of need for any secondary procedure after 1 year and demonstrated 91% of patients with PDGF fusions achieving clinical success compared to 78% of those treated with autograft. 14 In another prospective randomized controlled trial (RCT) from the North American Orthopedic Foot and Ankle Study Group, 434 patients were randomized (2:1) to rhPDGF or autograft-augmented fusion of the ankle or hindfoot. In the cohort that received rhPDGF, the fusion rate, as determined by CT scan at 6 months, was 62.0% (159/260 patients).…”
Section: Demineralized Bone Matrixmentioning
confidence: 99%